3//SEC Filing
Cormorant Private Healthcare Fund II, LP 3
Accession 0001567619-20-012042
CIK 0001599901other
Filed
Jun 10, 8:00 PM ET
Accepted
Jun 11, 8:26 PM ET
Size
11.2 KB
Accession
0001567619-20-012042
Insider Transaction Report
Form 3
Holdings
- (indirect: See Footnotes)
Series C Convertible Preferred Stock
→ Common Stock (2,214,545 underlying)
Footnotes (3)
- [F1]The Series C Convertible Preferred Stock is convertible at any time at the holder's election, without payment of additional consideration, and has no expiration date but is expected to convert automatically upon the closing of the Issuer's initial public offering.
- [F2]Shares of Series C Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 419,877 shares held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), (ii) 1,762,115 shares held by Cormorant Private Healthcare Fund II, LP ("Fund II"), and (iii) 32,553 shares held by a managed account (the "Account").
- [F3]Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Documents
Issuer
Avidity Biosciences, Inc.
CIK 0001599901
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001747677
Filing Metadata
- Form type
- 3
- Filed
- Jun 10, 8:00 PM ET
- Accepted
- Jun 11, 8:26 PM ET
- Size
- 11.2 KB